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Introduction 
 
 The ATS/ERS/JRS/ALAT recently released a new clinical practice guideline 
(ATS/ERS/JRS/ALAT2018) for idiopathic pulmonary fibrosis (IPF) with simultaneously 
proposed diagnostic criteria by the Fleischner Society. [1,2] Both diagnostic algorithms agree 
on most diagnostic steps, with divergent recommendations on the position of surgical lung 
biopsy (SLB): ATS/ERS/JRS/ALAT2018 recommends SLB in most patients with probable 
usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) 
(conditional recommendation), whereas the Fleischner society proposes to forgo SLB in 
patients with definite or probable UIP HRCT pattern, presenting in the right clinical context. 
[3,4] We aimed to quantify the impact of the previous (ATS/ERS/JRS/ALAT2011) [5] and the 
two new diagnostic approaches [1,2] on real-life clinical practice, with assessment of 
radiological inter-rater agreement, diagnostic test characteristics, and prognostic validity of 
the diverging radiological diagnoses for a multidisciplinary IPF diagnosis in our cohort. 
Methods 
We included patients with a multidisciplinary team (MDT) diagnosis of IPF from our 
cohort study, [6] and a clinically relevant control group of patients with fibrosing interstitial 
lung diseases, (chronic hypersensitivity pneumonitis-cHP and unclassifiable interstitial lung 
disease-ILD). Approval by the local ethics committee was obtained for data acquisition 
(Swiss Ethics Committee, Bern, KEK 246/15 PB_2016-01524).  
Three subspecialized thoracic radiologists reviewed the HRCT scans blinded to the initial 
classification, clinical diagnosis, and patient characteristics. During the first read out, raters 
classified the patterns according to the 2011 criteria: 1. Definitive UIP pattern; 2. Possible 
UIP pattern; and 3. Inconsistent with UIP pattern. Four weeks later, the radiologists received 
a re-randomized case collection for a second interpretation round according to the Fleischner 
and subsequently the ATS/ERS/JRS/ALAT2018 recommendations: 1. Typical UIP pattern; 2. 
Probable UIP pattern; 3. Indeterminate for UIP; and 4. Alternative diagnosis.  
For this analysis, we compared the three radiological scenarios allowing an IPF diagnosis 
without SLB in most patients: A definite UIP pattern according to ATS/ERS/JRS/ALAT2011 
and ATS/ERS/JRS/ALAT2018, and a definite or probable UIP pattern according to 
Fleischner. Inter-rater agreement between the three radiologists was assessed using Light-
Kappa (κ), which is an extension of Cohen’s Kappa for more than two raters. [7] Every 
radiological pattern was dichotomized (e.g. definite UIP YES/NO), and we considered a 
pattern to be present if 2-3 out of 3 radiologists scored the pattern with YES, otherwise the 
pattern was scored not to be present (NO). Test characteristics with 95% confidence 
intervals (95%CI) of the radiological scenarios against the MDT diagnosis of IPF as a 
reference standard were determined, including sensitivity, specificity, positive and negative 
predictive values (PPV, NPV), and Youden’s index which summarizes the diagnostic test 
performance. We assessed the prognostic validity of the three radiological scenarios by 
estimation of their effect on time to death using Cox proportional hazards models.  
Results 
We included 52 patients with IPF (MDT diagnosis), and 37 with non-IPF ILD. Baseline 
characteristics of patients with IPF and other ILDs were similar. Out of 89 patients in total, 70 
were men (79%); 56 were ever-smokers (63%); the mean age was 68.4 years (standard 
deviation [SD] 10.4); mean body mass index 27.2 (SD 4.8) kg/m2; mean forced vital capacity 
68.4 (SD 19.0) %-predicted; mean diffusing capacity of the lung for carbon monoxide (DLCO) 
50 (SD 16.7) %-predicted; with SLB available in 19 (33%) IPF and 21 (57%) patients with 
other ILDs. During follow-up (mean 26.9 [interquartile range 17.2-50.2] months) 28 (54%) of 
all IPF and 2 (5.4%) of other ILD patients deceased.  
The overall interrater agreement was good for ATS/ERS/JRS/ALAT2011 (κ 0.61), and 
moderate for ATS/ERS/JRS/ALAT2018 and Fleischner (κ 0.54 and 0.57 respectively).  
Diagnostic test characteristics for the MDT-IPF diagnosis demonstrated a high 
specificity for all three radiological scenarios. Fleischner misclassified 4/37 non-IPF cases as 
IPF, compared to 3/37 and 1/37 misclassifications with ATS/ERS/JRS/ALAT2018 and 
ATS/ERS/JRS/ALAT2011, respectively.  Sensitivity was markedly higher for the Fleischner 
scenario with 7/52 missed IPF cases, compared to ATS/ERS/JRS/ALAT2018 and 
ATS/ERS/JRS/ALAT2011 with 20/52 and 23/52 missed IPF cases respectively. PPV and 
NPV was slightly higher for Fleischner than for ATS/ERS/JRS/ALAT2018, and of all 
scenarios, Fleischner had the strongest overall test performance (Table).  
Patients with IPF had significantly worse survival: MDT-IPF diagnosis was associated 
with a 16-fold increased risk of death compared to cHP and unclassifiable ILD (95%CI 3.7-
68.9). All radiological scenarios significantly correlated with survival in unadjusted analysis, 
with Fleischner scoring (definite and probable UIP) having the largest impact on mortality 
(HR 4.00, 95%CI 1.69-9.53, Table). Fleischner scenario remained the strongest correlate of 
mortality risk including with adjustment for potential confounders (age, sex, ever smoker, and 
DLCO %-predicted [HR 3.76, 95%CI 1.22-11.6, model C-index 0.80]). Corresponding 
multivariate Cox regression models demonstrated the ATS2011 scenario to be independently 
associated with survival (HR 2.87, 95%CI 1.06-7.78, model C-index 0.81), whereas 
ATS/ERS/JRS/ALAT2018 lost statistical significance in the adjusted model (HR 2.01, 95%CI 
0.71-5.68, model C-index 0.80).  
Discussion 
In the light of changing paradigms in IPF management, the clinical diagnostic 
approach to patients with suspected IPF has recently been discussed by the Fleischner 
Society and the ATS/ERS/JRS/ALAT, culminating in the publication of two, slightly different 
new diagnostic strategies [1,2]. We compared the clinical impact of the specific 
ATS/ERS/JRS/ALAT2011, ATS/ERS/JRS/ALAT2018, and Fleischner radiological scenarios 
that allow clinical IPF diagnosis without SLB in most patients. Fleischner differs from the 
ATS/ERS/JRS/ALAT algorithms by accepting not only definite, but as well probable UIP 
pattern for IPF diagnosis in the right clinical context. In our cohort of well- characterized IPF 
patients compared to a control group, we demonstrate a good diagnostic accuracy of the 
Fleischner approach for MDT diagnosis of IPF, with a prognostic discrimination that markedly 
strengthens its validity. 
Comparable to our findings from ATS/ERS/JRS/ALAT2011 und 2018 scoring, previous 
studies reported definite UIP as a highly specific but less sensitive marker for diagnosis of 
IPF, with clinical trials including patients without definite HRCT UIP pattern. [8,9] In this 
cohort, including patients with a probable UIP pattern to the subgroup not requiring SLB in 
the diagnostic algorithm results in a significantly higher sensitivity with only marginal loss in 
specificity (incremental misclassification in 2.7%). Applying the Fleischner algorithm, we 
further found an increase in PPV and NPV compared to ATS/ERS/JRS/ALAT2018, with the 
limitation that these characteristics are not generalizable to cohorts with different IPF 
prevalences. [10] Patients’ course of disease and survival supports IPF diagnosis. [11] We 
demonstrate that although the MDT-IPF diagnosis remains the strongest predictor of 
survival, the three radiological scenarios significantly correlated with mortality. In contrast to 
ATS/ERS/JRS/ALAT2018, the Fleischner radiological scenario was associated with risk of 
death independent from clinical baseline characteristics. Beyond the prognostic importance, 
this strengthens the diagnostic validity of the combination of definite and probable HRCT UIP 
for clinical IPF diagnosis.  
Our work confirms moderate inter-observer agreement between expert radiologists for 
definite and probable UIP pattern according to previous and current guidelines. [12,13] This 
subjective component in radiological diagnosis might be problematic if integrated in clinical 
decision making on further invasive diagnostic procedures. Semi-automated CT readings 
might address this issue in the future. [14] Regardless, the potential benefit of the added 
pathological information still needs to be balanced carefully against the risks of invasive 
procedures such as SLB, particularly in elderly patients with severely impaired pulmonary 
function or significant comorbidities. The Fleischner diagnostic approach might reduce the 
percentage of patients with suspected IPF needing an invasive procedure, and data from our 
cohort support its diagnostic and prognostic validity in clinical routine.  
Future prospective studies are needed to validate different decision algorithms 
incorporating non-invasive and if needed invasive biomarkers with inclusion of patient 
preference in the process.  
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Table. Diagnostic and prognostic performance of radiological scenarios.  
 
 
*Diagnostic test characteristics with IPF MDT diagnosis as the reference standard.  
†Definite UIP scored according to ATS/ERS/JRS/ALAT2011 and ATS/ERS/JRS/ALAT2018 
guidelines respectively  
‡Definite and probable UIPs scored according to the recommendations by the Fleischner 
Society. 
 
Abbreviations: CI, confidence interval; C-index, Harrell’s concordance statistic; HR, hazard 
ratio; IPF, idiopathic pulmonary fibrosis; J-index, Youden’s J statistic; NPV, negative 
predictive value; PPV, positive predictive value; UIP, usual interstitial pneumonia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Test characteristics* Survival (unadjusted) 
Radiological 
scenario 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
PPV 
(95%CI) 
NPV 
(95%CI) 
J-index 
(95%CI) 
HR 
(95% CI) 
p-value C-index 
ATS/ERS/JRS/
ALAT 2011
†
 
0.56 
(0.41-0.70) 
 
0.97 
(0.86-1.00) 
 
0.97 
(0.83-1.00) 
 
0.61 
(0.47-0.73) 
 
0.53 
(0.27-0.69) 
 
3.21 
(1.54-6.67) 
0.001 0.66 
ATS/ERS/JRS/
ALAT 2018
†
 
0.62 
(0.47-0.75) 
 
0.92 
(0.78-0.98) 
 
0.91 
(0.77-0.98) 
 
0.63 
(0.49-0.76) 
 
0.53 
(0.25-0.73) 
3.26 
(1.55-6.85) 
0.002 0.64 
Fleischner
‡
  0.87 
(0.74-0.94) 
 
0.89 
(0.75-0.97) 
 
0.92 
(0.80-0.98) 
 
0.82 
(0.67-0.93) 
 
0.75 
(0.49-0.91) 
 
4.00 
(1.69-9.53) 
0.002 0.66 
